KR102086709B1 - 뇌신경의 이개 마취에 의한 질병의 치료 방법 - Google Patents
뇌신경의 이개 마취에 의한 질병의 치료 방법 Download PDFInfo
- Publication number
- KR102086709B1 KR102086709B1 KR1020157033239A KR20157033239A KR102086709B1 KR 102086709 B1 KR102086709 B1 KR 102086709B1 KR 1020157033239 A KR1020157033239 A KR 1020157033239A KR 20157033239 A KR20157033239 A KR 20157033239A KR 102086709 B1 KR102086709 B1 KR 102086709B1
- Authority
- KR
- South Korea
- Prior art keywords
- pharmaceutical composition
- subject
- delete delete
- nerve
- pain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 105
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 47
- 201000010099 disease Diseases 0.000 title claims abstract description 39
- 206010002091 Anaesthesia Diseases 0.000 title abstract description 15
- 230000037005 anaesthesia Effects 0.000 title abstract description 15
- 210000003792 cranial nerve Anatomy 0.000 title description 18
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 84
- 210000000613 ear canal Anatomy 0.000 claims abstract description 42
- 210000005036 nerve Anatomy 0.000 claims description 59
- 210000001186 vagus nerve Anatomy 0.000 claims description 47
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 claims description 42
- 208000006673 asthma Diseases 0.000 claims description 27
- VEQOALNAAJBPNY-UHFFFAOYSA-N antipyrine Chemical compound CN1C(C)=CC(=O)N1C1=CC=CC=C1 VEQOALNAAJBPNY-UHFFFAOYSA-N 0.000 claims description 25
- 229960005222 phenazone Drugs 0.000 claims description 25
- 229960005274 benzocaine Drugs 0.000 claims description 21
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N Aminoantipyrine Natural products CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 claims description 16
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims description 11
- 208000008589 Obesity Diseases 0.000 claims description 10
- 235000020824 obesity Nutrition 0.000 claims description 10
- 206010011224 Cough Diseases 0.000 claims description 8
- 206010013952 Dysphonia Diseases 0.000 claims description 7
- 230000036528 appetite Effects 0.000 claims description 7
- 235000019789 appetite Nutrition 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- 206010061428 decreased appetite Diseases 0.000 claims description 6
- 230000003880 negative regulation of appetite Effects 0.000 claims description 6
- 210000004556 brain Anatomy 0.000 claims description 5
- 235000013305 food Nutrition 0.000 claims description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 230000001766 physiological effect Effects 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 206010067672 Spasmodic dysphonia Diseases 0.000 claims description 2
- 239000003242 anti bacterial agent Substances 0.000 claims description 2
- 229940088710 antibiotic agent Drugs 0.000 claims description 2
- 230000037406 food intake Effects 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 201000002849 spasmodic dystonia Diseases 0.000 claims description 2
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 2
- 230000008035 nerve activity Effects 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 6
- 230000001815 facial effect Effects 0.000 abstract description 3
- 229940005553 analgesics and anesthetics Drugs 0.000 abstract description 2
- 239000006196 drop Substances 0.000 description 29
- 230000036407 pain Effects 0.000 description 28
- 208000002193 Pain Diseases 0.000 description 26
- 210000000256 facial nerve Anatomy 0.000 description 21
- 230000001953 sensory effect Effects 0.000 description 19
- 208000003098 Ganglion Cysts Diseases 0.000 description 17
- 208000005400 Synovial Cyst Diseases 0.000 description 17
- 210000003901 trigeminal nerve Anatomy 0.000 description 14
- 238000007483 tonsillectomy Methods 0.000 description 12
- 239000000835 fiber Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 208000007101 Muscle Cramp Diseases 0.000 description 10
- 230000006870 function Effects 0.000 description 9
- 238000001356 surgical procedure Methods 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 230000033228 biological regulation Effects 0.000 description 8
- 206010006451 bronchitis Diseases 0.000 description 8
- 238000009826 distribution Methods 0.000 description 8
- 208000007882 Gastritis Diseases 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 7
- 206010023848 Laryngeal pain Diseases 0.000 description 7
- 206010068319 Oropharyngeal pain Diseases 0.000 description 7
- 208000005141 Otitis Diseases 0.000 description 7
- 230000002920 convulsive effect Effects 0.000 description 7
- 208000019258 ear infection Diseases 0.000 description 7
- 210000001508 eye Anatomy 0.000 description 7
- 210000000609 ganglia Anatomy 0.000 description 7
- 230000004054 inflammatory process Effects 0.000 description 7
- 210000004731 jugular vein Anatomy 0.000 description 7
- 210000003254 palate Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 208000004998 Abdominal Pain Diseases 0.000 description 6
- 208000019901 Anxiety disease Diseases 0.000 description 6
- 206010013935 Dysmenorrhoea Diseases 0.000 description 6
- 230000003444 anaesthetic effect Effects 0.000 description 6
- 210000003484 anatomy Anatomy 0.000 description 6
- 230000036506 anxiety Effects 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 6
- 230000000903 blocking effect Effects 0.000 description 6
- 230000002354 daily effect Effects 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 210000003127 knee Anatomy 0.000 description 6
- 208000004296 neuralgia Diseases 0.000 description 6
- 210000001331 nose Anatomy 0.000 description 6
- 210000000056 organ Anatomy 0.000 description 6
- 206010041232 sneezing Diseases 0.000 description 6
- 206010009137 Chronic sinusitis Diseases 0.000 description 5
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 5
- 208000019505 Deglutition disease Diseases 0.000 description 5
- 206010061818 Disease progression Diseases 0.000 description 5
- 208000012661 Dyskinesia Diseases 0.000 description 5
- 206010028735 Nasal congestion Diseases 0.000 description 5
- 208000000450 Pelvic Pain Diseases 0.000 description 5
- 206010039085 Rhinitis allergic Diseases 0.000 description 5
- 208000005279 Status Asthmaticus Diseases 0.000 description 5
- 208000024716 acute asthma Diseases 0.000 description 5
- 208000002205 allergic conjunctivitis Diseases 0.000 description 5
- 201000010105 allergic rhinitis Diseases 0.000 description 5
- 208000024998 atopic conjunctivitis Diseases 0.000 description 5
- 208000027157 chronic rhinosinusitis Diseases 0.000 description 5
- 201000003146 cystitis Diseases 0.000 description 5
- 230000005750 disease progression Effects 0.000 description 5
- 239000003193 general anesthetic agent Substances 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 210000003800 pharynx Anatomy 0.000 description 5
- 230000011514 reflex Effects 0.000 description 5
- 206010039083 rhinitis Diseases 0.000 description 5
- 206010042772 syncope Diseases 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000001319 vasomotor rhinitis Diseases 0.000 description 5
- 230000009278 visceral effect Effects 0.000 description 5
- 208000009079 Bronchial Spasm Diseases 0.000 description 4
- 208000005171 Dysmenorrhea Diseases 0.000 description 4
- 206010014020 Ear pain Diseases 0.000 description 4
- 201000008197 Laryngitis Diseases 0.000 description 4
- 208000019695 Migraine disease Diseases 0.000 description 4
- 206010028813 Nausea Diseases 0.000 description 4
- 206010063080 Postural orthostatic tachycardia syndrome Diseases 0.000 description 4
- 208000005392 Spasm Diseases 0.000 description 4
- 239000000730 antalgic agent Substances 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 208000006218 bradycardia Diseases 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 4
- 210000001072 colon Anatomy 0.000 description 4
- 210000001932 glossopharyngeal nerve Anatomy 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 235000012054 meals Nutrition 0.000 description 4
- 230000008693 nausea Effects 0.000 description 4
- 210000000496 pancreas Anatomy 0.000 description 4
- 210000005037 parasympathetic nerve Anatomy 0.000 description 4
- 230000035790 physiological processes and functions Effects 0.000 description 4
- 208000015768 polyposis Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000008961 swelling Effects 0.000 description 4
- 206010003805 Autism Diseases 0.000 description 3
- 208000020706 Autistic disease Diseases 0.000 description 3
- 206010048994 Bladder spasm Diseases 0.000 description 3
- 206010006458 Bronchitis chronic Diseases 0.000 description 3
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 3
- 229920000742 Cotton Polymers 0.000 description 3
- 208000004483 Dyspareunia Diseases 0.000 description 3
- 208000008967 Enuresis Diseases 0.000 description 3
- 208000001640 Fibromyalgia Diseases 0.000 description 3
- 206010019233 Headaches Diseases 0.000 description 3
- 208000031361 Hiccup Diseases 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 208000001953 Hypotension Diseases 0.000 description 3
- 208000009612 Laryngismus Diseases 0.000 description 3
- 206010023891 Laryngospasm Diseases 0.000 description 3
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 3
- 208000005793 Restless legs syndrome Diseases 0.000 description 3
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 3
- 206010041235 Snoring Diseases 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 229940035674 anesthetics Drugs 0.000 description 3
- 230000036471 bradycardia Effects 0.000 description 3
- 208000023819 chronic asthma Diseases 0.000 description 3
- 208000007451 chronic bronchitis Diseases 0.000 description 3
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 201000006549 dyspepsia Diseases 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 210000003128 head Anatomy 0.000 description 3
- 230000036543 hypotension Effects 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 210000001847 jaw Anatomy 0.000 description 3
- 229960004194 lidocaine Drugs 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 230000027939 micturition Effects 0.000 description 3
- 206010027599 migraine Diseases 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 3
- 210000004126 nerve fiber Anatomy 0.000 description 3
- 230000001537 neural effect Effects 0.000 description 3
- 230000001734 parasympathetic effect Effects 0.000 description 3
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 3
- JEXVQSWXXUJEMA-UHFFFAOYSA-N pyrazol-3-one Chemical class O=C1C=CN=N1 JEXVQSWXXUJEMA-UHFFFAOYSA-N 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000002271 resection Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 239000011435 rock Substances 0.000 description 3
- 230000035807 sensation Effects 0.000 description 3
- 235000019615 sensations Nutrition 0.000 description 3
- 230000019491 signal transduction Effects 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000035900 sweating Effects 0.000 description 3
- 210000000427 trigeminal ganglion Anatomy 0.000 description 3
- 210000003454 tympanic membrane Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 206010058841 Adnexa uteri pain Diseases 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 2
- 206010052384 Biliary cyst Diseases 0.000 description 2
- 206010005052 Bladder irritation Diseases 0.000 description 2
- 208000032841 Bulimia Diseases 0.000 description 2
- 206010006550 Bulimia nervosa Diseases 0.000 description 2
- 206010008479 Chest Pain Diseases 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010009900 Colitis ulcerative Diseases 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 201000003883 Cystic fibrosis Diseases 0.000 description 2
- 208000014094 Dystonic disease Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 208000030644 Esophageal Motility disease Diseases 0.000 description 2
- 208000037767 Gallbladder pain Diseases 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 201000005624 HELLP Syndrome Diseases 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- 208000009233 Morning Sickness Diseases 0.000 description 2
- 208000001089 Multiple system atrophy Diseases 0.000 description 2
- 206010028836 Neck pain Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 2
- 206010030180 Oesophageal pain Diseases 0.000 description 2
- 206010031127 Orthostatic hypotension Diseases 0.000 description 2
- 206010033664 Panic attack Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- YQKAVWCGQQXBGW-UHFFFAOYSA-N Piperocaine Chemical compound CC1CCCCN1CCCOC(=O)C1=CC=CC=C1 YQKAVWCGQQXBGW-UHFFFAOYSA-N 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 206010036772 Proctalgia Diseases 0.000 description 2
- 206010057011 Rectal spasm Diseases 0.000 description 2
- 206010038490 Renal pain Diseases 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 208000009205 Tinnitus Diseases 0.000 description 2
- 208000000323 Tourette Syndrome Diseases 0.000 description 2
- 208000016620 Tourette disease Diseases 0.000 description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 description 2
- 206010046788 Uterine haemorrhage Diseases 0.000 description 2
- 206010046823 Uterine spasm Diseases 0.000 description 2
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 208000034850 Vomiting in pregnancy Diseases 0.000 description 2
- 201000010550 acute laryngitis Diseases 0.000 description 2
- 210000000133 brain stem Anatomy 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 206010061592 cardiac fibrillation Diseases 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000004004 carotid artery internal Anatomy 0.000 description 2
- 210000005056 cell body Anatomy 0.000 description 2
- 201000009243 chronic laryngitis Diseases 0.000 description 2
- 208000013507 chronic prostatitis Diseases 0.000 description 2
- 229960001747 cinchocaine Drugs 0.000 description 2
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 2
- 229960003920 cocaine Drugs 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 229950010160 dimethocaine Drugs 0.000 description 2
- OWQIUQKMMPDHQQ-UHFFFAOYSA-N dimethocaine Chemical compound CCN(CC)CC(C)(C)COC(=O)C1=CC=C(N)C=C1 OWQIUQKMMPDHQQ-UHFFFAOYSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 201000011191 dyskinesia of esophagus Diseases 0.000 description 2
- 208000010118 dystonia Diseases 0.000 description 2
- 206010013990 dysuria Diseases 0.000 description 2
- -1 ebudocaine Chemical compound 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000003238 esophagus Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 238000002513 implantation Methods 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 238000012977 invasive surgical procedure Methods 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 210000004874 lower jaw Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000001617 median nerve Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 208000019906 panic disease Diseases 0.000 description 2
- 230000001314 paroxysmal effect Effects 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 229960001045 piperocaine Drugs 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 208000028173 post-traumatic stress disease Diseases 0.000 description 2
- 201000011461 pre-eclampsia Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 229960004919 procaine Drugs 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 210000003079 salivary gland Anatomy 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 208000019116 sleep disease Diseases 0.000 description 2
- 230000000392 somatic effect Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000009747 swallowing Effects 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 229960002372 tetracaine Drugs 0.000 description 2
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 2
- 231100000886 tinnitus Toxicity 0.000 description 2
- 238000002627 tracheal intubation Methods 0.000 description 2
- 210000005166 vasculature Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- ZKMNUMMKYBVTFN-HNNXBMFYSA-N (S)-ropivacaine Chemical compound CCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C ZKMNUMMKYBVTFN-HNNXBMFYSA-N 0.000 description 1
- XBYRMPXUBGMOJC-UHFFFAOYSA-N 1,2-dihydropyrazol-3-one Chemical compound OC=1C=CNN=1 XBYRMPXUBGMOJC-UHFFFAOYSA-N 0.000 description 1
- ZRHUHDUEXWHZMA-UHFFFAOYSA-N 1,4-dihydropyrazol-5-one Chemical compound O=C1CC=NN1 ZRHUHDUEXWHZMA-UHFFFAOYSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- RMMXTBMQSGEXHJ-UHFFFAOYSA-N Aminophenazone Chemical compound O=C1C(N(C)C)=C(C)N(C)N1C1=CC=CC=C1 RMMXTBMQSGEXHJ-UHFFFAOYSA-N 0.000 description 1
- QTGIAADRBBLJGA-UHFFFAOYSA-N Articaine Chemical compound CCCNC(C)C(=O)NC=1C(C)=CSC=1C(=O)OC QTGIAADRBBLJGA-UHFFFAOYSA-N 0.000 description 1
- 208000012219 Autonomic Nervous System disease Diseases 0.000 description 1
- 206010003840 Autonomic nervous system imbalance Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- 241001269524 Dura Species 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000027109 Headache disease Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000013016 Hypoglycemia Diseases 0.000 description 1
- 206010028391 Musculoskeletal Pain Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 206010028413 Myalgia intercostal Diseases 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 208000014934 Oesophageal motility disease Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- KCLANYCVBBTKTO-UHFFFAOYSA-N Proparacaine Chemical compound CCCOC1=CC=C(C(=O)OCCN(CC)CC)C=C1N KCLANYCVBBTKTO-UHFFFAOYSA-N 0.000 description 1
- CAJIGINSTLKQMM-UHFFFAOYSA-N Propoxycaine Chemical compound CCCOC1=CC(N)=CC=C1C(=O)OCCN(CC)CC CAJIGINSTLKQMM-UHFFFAOYSA-N 0.000 description 1
- 201000002154 Pterygium Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010051958 Ureteral spasm Diseases 0.000 description 1
- 210000003489 abdominal muscle Anatomy 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000002534 adenoid Anatomy 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229960000212 aminophenazone Drugs 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 229960003831 articaine Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 210000001326 carotid sinus Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000003198 cerebellar cortex Anatomy 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 208000029771 childhood onset asthma Diseases 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004741 cyclomethycaine Drugs 0.000 description 1
- YLRNESBGEGGQBK-UHFFFAOYSA-N cyclomethycaine Chemical compound CC1CCCCN1CCCOC(=O)C(C=C1)=CC=C1OC1CCCCC1 YLRNESBGEGGQBK-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229940120889 dipyrone Drugs 0.000 description 1
- 208000032625 disorder of ear Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 210000000883 ear external Anatomy 0.000 description 1
- 230000001856 erectile effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 210000001097 facial muscle Anatomy 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000002518 glial effect Effects 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000004561 lacrimal apparatus Anatomy 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229960004288 levobupivacaine Drugs 0.000 description 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000003784 masticatory muscle Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000005499 meniscus Effects 0.000 description 1
- DJGAAPFSPWAYTJ-UHFFFAOYSA-M metamizole sodium Chemical compound [Na+].O=C1C(N(CS([O-])(=O)=O)C)=C(C)N(C)N1C1=CC=CC=C1 DJGAAPFSPWAYTJ-UHFFFAOYSA-M 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 208000013465 muscle pain Diseases 0.000 description 1
- 210000001087 myotubule Anatomy 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 208000005346 nocturnal enuresis Diseases 0.000 description 1
- 229940053973 novocaine Drugs 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 210000003695 paranasal sinus Anatomy 0.000 description 1
- 210000003681 parotid gland Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000006461 physiological response Effects 0.000 description 1
- 206010036596 premature ejaculation Diseases 0.000 description 1
- 229960001807 prilocaine Drugs 0.000 description 1
- MVFGUOIZUNYYSO-UHFFFAOYSA-N prilocaine Chemical compound CCCNC(C)C(=O)NC1=CC=CC=C1C MVFGUOIZUNYYSO-UHFFFAOYSA-N 0.000 description 1
- 229960003981 proparacaine Drugs 0.000 description 1
- 229950003255 propoxycaine Drugs 0.000 description 1
- 229960002189 propyphenazone Drugs 0.000 description 1
- PXWLVJLKJGVOKE-UHFFFAOYSA-N propyphenazone Chemical compound O=C1C(C(C)C)=C(C)N(C)N1C1=CC=CC=C1 PXWLVJLKJGVOKE-UHFFFAOYSA-N 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 229960001549 ropivacaine Drugs 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 210000000331 sympathetic ganglia Anatomy 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 210000003582 temporal bone Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 229950002569 trimecaine Drugs 0.000 description 1
- GOZBHBFUQHMKQB-UHFFFAOYSA-N trimecaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=C(C)C=C1C GOZBHBFUQHMKQB-UHFFFAOYSA-N 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 210000004760 visceral afferent Anatomy 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- 230000001755 vocal effect Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0046—Ear
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361819023P | 2013-05-03 | 2013-05-03 | |
| US61/819,023 | 2013-05-03 | ||
| PCT/US2014/036855 WO2014179814A1 (en) | 2013-05-03 | 2014-05-05 | Method of treating disease by auricular anesthesia of cranial nerves |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20160003012A KR20160003012A (ko) | 2016-01-08 |
| KR102086709B1 true KR102086709B1 (ko) | 2020-03-09 |
Family
ID=51844020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020157033239A Active KR102086709B1 (ko) | 2013-05-03 | 2014-05-05 | 뇌신경의 이개 마취에 의한 질병의 치료 방법 |
| KR1020187015606A Active KR102796310B1 (ko) | 2013-05-03 | 2016-11-02 | 뇌신경의 귀 마취에 의해 질환을 치료하는 방법 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020187015606A Active KR102796310B1 (ko) | 2013-05-03 | 2016-11-02 | 뇌신경의 귀 마취에 의해 질환을 치료하는 방법 |
Country Status (17)
| Country | Link |
|---|---|
| US (4) | US20140357686A1 (enExample) |
| EP (2) | EP2991620B1 (enExample) |
| JP (3) | JP6433985B2 (enExample) |
| KR (2) | KR102086709B1 (enExample) |
| CN (2) | CN105163718B (enExample) |
| AU (2) | AU2014262148B2 (enExample) |
| CA (2) | CA2910422C (enExample) |
| DK (1) | DK2991620T3 (enExample) |
| ES (1) | ES2823624T3 (enExample) |
| HK (1) | HK1212230A1 (enExample) |
| IL (2) | IL242339B (enExample) |
| MX (2) | MX381106B (enExample) |
| MY (2) | MY180310A (enExample) |
| RU (2) | RU2687249C2 (enExample) |
| SG (1) | SG11201508509XA (enExample) |
| WO (2) | WO2014179814A1 (enExample) |
| ZA (2) | ZA201508782B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180088408A (ko) * | 2013-05-03 | 2018-08-03 | 토마스 엠. 크루즈 | 뇌신경의 귀 마취에 의해 질환을 치료하는 방법 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3263103A4 (en) * | 2015-02-26 | 2018-03-14 | Limited Liability Company "konsortsium-pik" | Pharmaceutical composition for treatment of inflammatory ear diseases, method for producing same and method for treatment using said composition |
| KR102630701B1 (ko) | 2016-09-07 | 2024-01-29 | 글리아, 엘엘씨 | 두개 신경의 약리학적 피부 활성화에 의한 신경변성 질환과 관련된 증상의 치료 |
| US20220105052A1 (en) * | 2016-12-26 | 2022-04-07 | Cellix Bio Private Limited | Compositions and methods for the treatment of chronic pain |
| CN107789621A (zh) * | 2017-12-15 | 2018-03-13 | 阜阳市平衡医疗保健器械有限公司 | 一种治疗头痛的药物及其配制方法 |
| US11607275B2 (en) * | 2019-05-20 | 2023-03-21 | Medtronic Ireland Manufacturing Unlimited Company | Selection of hypertensive patients for treatment with renal denervation |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19524691A1 (de) * | 1995-07-06 | 1997-01-09 | Liedtke Pharmed Gmbh | Methode und Zusammensetzung einer topischen Therapie von Innenohr und Labyrinth-Symptomen |
| RU2104056C1 (ru) * | 1995-07-10 | 1998-02-10 | Александр Александрович Ланцов | Способ лечения периферических поражений лицевого нерва |
| JPH1094613A (ja) * | 1996-08-02 | 1998-04-14 | Mieko Sato | 食欲調整用具 |
| US6093417A (en) * | 1999-01-11 | 2000-07-25 | Advanced Medical Instruments | Composition to treat ear disorders |
| ATE541565T1 (de) * | 1999-05-27 | 2012-02-15 | Khoury George F El | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus |
| DE10322497A1 (de) * | 2003-05-19 | 2004-12-09 | Liedtke, Rainer K., Dr. | Topisch pharmakologische Vorbeugung und Therapie der Hyperakusis |
| US8940321B2 (en) * | 2003-12-12 | 2015-01-27 | Otic Pharma Ltd. | Compositions for treatment of ear disorders and methods of use thereof |
| US8755892B2 (en) * | 2007-05-16 | 2014-06-17 | Cardiac Pacemakers, Inc. | Systems for stimulating neural targets |
| WO2011019954A2 (en) * | 2009-08-13 | 2011-02-17 | Yehuda Ivri | Intracochlear drug delivery to the central nervous system |
| WO2011028915A2 (en) * | 2009-09-03 | 2011-03-10 | University Of Chicago | Platelet aggregation inhibitors |
| WO2013040352A1 (en) * | 2011-09-15 | 2013-03-21 | Yoseph Yaacobi | Systems and methods for treating ear disorders |
| DK2991620T3 (da) * | 2013-05-03 | 2020-10-12 | Thomas M Crews | Kombinationer af antipyrin og benzocain til behandling af sygdomme forbundet med en kranienerve |
-
2014
- 2014-05-05 DK DK14791131.7T patent/DK2991620T3/da active
- 2014-05-05 CN CN201480024269.1A patent/CN105163718B/zh active Active
- 2014-05-05 JP JP2016512111A patent/JP6433985B2/ja active Active
- 2014-05-05 HK HK16100269.6A patent/HK1212230A1/xx unknown
- 2014-05-05 SG SG11201508509XA patent/SG11201508509XA/en unknown
- 2014-05-05 US US14/270,238 patent/US20140357686A1/en not_active Abandoned
- 2014-05-05 AU AU2014262148A patent/AU2014262148B2/en active Active
- 2014-05-05 KR KR1020157033239A patent/KR102086709B1/ko active Active
- 2014-05-05 EP EP14791131.7A patent/EP2991620B1/en active Active
- 2014-05-05 WO PCT/US2014/036855 patent/WO2014179814A1/en not_active Ceased
- 2014-05-05 MX MX2015015194A patent/MX381106B/es unknown
- 2014-05-05 ES ES14791131T patent/ES2823624T3/es active Active
- 2014-05-05 RU RU2015148757A patent/RU2687249C2/ru active
- 2014-05-05 MY MYPI2015002669A patent/MY180310A/en unknown
- 2014-05-05 CA CA2910422A patent/CA2910422C/en active Active
-
2015
- 2015-10-29 IL IL242339A patent/IL242339B/en active IP Right Grant
- 2015-11-03 US US14/931,581 patent/US9968589B2/en active Active
- 2015-12-01 ZA ZA2015/08782A patent/ZA201508782B/en unknown
-
2016
- 2016-11-02 EP EP16862858.4A patent/EP3370716A4/en active Pending
- 2016-11-02 WO PCT/US2016/060085 patent/WO2017079270A1/en not_active Ceased
- 2016-11-02 CA CA3004160A patent/CA3004160C/en active Active
- 2016-11-02 RU RU2018118068A patent/RU2701548C1/ru active
- 2016-11-02 CN CN201680077107.3A patent/CN108430470A/zh active Pending
- 2016-11-02 AU AU2016349784A patent/AU2016349784B2/en active Active
- 2016-11-02 MY MYPI2018701738A patent/MY196979A/en unknown
- 2016-11-02 KR KR1020187015606A patent/KR102796310B1/ko active Active
- 2016-11-02 JP JP2018543020A patent/JP2018536709A/ja active Pending
- 2016-11-02 MX MX2018005625A patent/MX390998B/es unknown
-
2018
- 2018-04-29 IL IL259019A patent/IL259019B/en active IP Right Grant
- 2018-05-14 US US15/978,742 patent/US11123284B2/en active Active
- 2018-05-25 ZA ZA2018/03483A patent/ZA201803483B/en unknown
-
2021
- 2021-09-20 US US17/479,780 patent/US20220387307A1/en not_active Abandoned
-
2022
- 2022-02-07 JP JP2022016897A patent/JP7512317B2/ja active Active
Non-Patent Citations (2)
| Title |
|---|
| Archives of Pediatrics and Adolescent Medicine 151(7):675-678 (1997) |
| International Journal of Pediatric Otorhinolaryngology 76(9):1229-1235 (2012) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180088408A (ko) * | 2013-05-03 | 2018-08-03 | 토마스 엠. 크루즈 | 뇌신경의 귀 마취에 의해 질환을 치료하는 방법 |
| KR102796310B1 (ko) * | 2013-05-03 | 2025-04-16 | 토마스 엠. 크루즈 | 뇌신경의 귀 마취에 의해 질환을 치료하는 방법 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102086709B1 (ko) | 뇌신경의 이개 마취에 의한 질병의 치료 방법 | |
| US9821164B2 (en) | Electrical treatment of bronchial constriction | |
| Loft et al. | Hiccups: a case presentation and etiologic review | |
| Jankovic | Regional nerve blocks and infiltration therapy: Textbook and color atlas | |
| NZ713746B2 (en) | Method of treating disease by auricular anesthesia of cranial nerves | |
| Angelova et al. | Innovative Approaches to the Treatment of Sleep Apnoea | |
| Russel | The treatment of diseases of the cranial nerves and organic lesions of the spinal cord. | |
| Bremer | The variability of the lesions in polioencephalomyelitis | |
| Shirley | Trigeminal Neuralgia Hypnotherapy for Pain Reduction: Two Case Studies. | |
| Campana | Some Symptoms And Complaints Encountered In Hyperextension-Hyperflexion Injuries (Whiplash) | |
| BR112018008893B1 (pt) | Composição farmacêutica óptica |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20151120 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| A302 | Request for accelerated examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20190507 Comment text: Request for Examination of Application |
|
| PA0302 | Request for accelerated examination |
Patent event date: 20190507 Patent event code: PA03022R01D Comment text: Request for Accelerated Examination |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20190821 Patent event code: PE09021S01D |
|
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20191204 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20200303 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20200304 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20250219 Start annual number: 6 End annual number: 6 |